Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
Status:
Completed
Trial end date:
2019-06-05
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ribociclib works in treating patients with
neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas,
that have spread to other places in the body and usually cannot be cured or controlled with
treatment (advanced tumors). Ribociclib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth.